| Document |
Document Title |
|
WO/2009/066457A1 |
Disclosed is an external preparation composition having good transdermal absorbability. An external preparation composition having excellent transdermal absorbability can be produced by dissolving a medicinal substance or a salt thereof ...
|
|
WO/2009/063223A1 |
The present invention relates to the use of one or more anti-bacterial compounds for the preparation of a medicament wherein the one or more anti-bacterial compounds exhibits an anaesthetic effect.
|
|
WO/2009/059989A1 |
The invention relates to aqueous emulsions comprising a hydrophobic active ingredient, to methods for the production thereof, pharmaceutical compositions, such as therapeutic agents, diagnostic agents, and/or prophylactic agents, in part...
|
|
WO/2009/052569A1 |
The present invention relates to a method and an apparatus for treating pain in a patient, such as a veterinary patient. The method comprises the step of administering an inhalation anaesthetic at sub-anaesthetic levels to the patient du...
|
|
WO/2009/049460A1 |
The use of a cyclo-olefin copolymer (COC) material for manufacturing a container used to store an anesthetic. Also a container, said container comprising a container body and a cap, wherein the material of the interior surface of said co...
|
|
WO/2002/026020A9 |
|
|
WO/2009/038514A1 |
A system and method to improve sensory functions in the hand or foot by dermal topical application of a local anaesthetic substance to adjacent skin areas, using a tailored application device or kit specially designed to fit the size and...
|
|
WO/2009/029618A1 |
Provided herein are compositions, combinations, and methods comprising NMDA antagonists including, but not limited to, NMDA glutamate receptor antagonists such as [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1-(7)-en-2-yl)alkyl
]phosphonic a...
|
|
WO/2009/024502A1 |
The invention relates to a compound of general formula (I) wherein is aryl or a five or six membered heteroaryl; is a six to nine membered mono or bi-heterocyclic group, wherein X may be a carbon atom, SO2 or a further hetero atom, selec...
|
|
WO/2009/025699A1 |
A topical medication garment, a system and a method provide topical medication. An impermeable garment may allow the topical medication to maintain contact with the skin of the user. The garment may prevent the topical medication from ab...
|
|
WO/2009/016269A1 |
The present invention concerns a novel water-soluble prodrug, ethyl dioxy phosphate of propofol, as well as the nontoxic pharmaceutically acceptable salts thereof, methods for preparing the prodrug, pharmaceutical compositions containing...
|
|
WO/2009/003255A1 |
The present patent application refers to pharmaceutical compositions comprising at least a semicarbazone or a thiosemicarbazone, or a pharmaceutically acceptable salt, hydrated or solvated thereof, for the treatment of inflammatory, febr...
|
|
WO/2008/144738A1 |
Methods for providing post-operative pain control or relief to a patient are disclosed. Methods include, for example, administering bicarbonate to an area of a patient during a surgical or dental procedure, near completion of a surgical ...
|
|
WO/2008/139078A2 |
The invention relates to a gaseous mixture containing oxygen and nitrous oxide in a nitrous oxide proportion of between 5 and 15 vol. %, that can be used for producing a drug for preventing or reducing hyperalgesia in human beings or ani...
|
|
WO/2008/136856A2 |
Biodegradable and resorbable polymer pouches are described for use with cardiac rhythm mamagent devices (CRMs) and other implantable medical devices (IMDs), i.e., a pouch, covering, or other receptacle capable of encasing, surrounding an...
|
|
WO/2008/132600A2 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and method...
|
|
WO/2008/134553A1 |
This invention is directed to methods of using bicyclic compounds of formula (I): wherein n, A, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable sa...
|
|
WO/2008/134525A1 |
Disclosed herein are substituted cyclohexanone-based NMDA receptor modulators of Formula (I), process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2008/125349A1 |
The present invention relates to compounds of formula (I) having pharmacological activity towards the sigma (σ) receptor, and more particularly to some spiro-pyrano-pyrazole derivatives, to processes of preparation of such compounds, to...
|
|
WO/2008/125348A1 |
The present invention relates to compounds of formula (I) having pharmacological activity towards the sigma (σ) receptor, and more particularly to Pyrano-pyrazol-amines, to processes of preparation of such compounds, to pharmaceutical c...
|
|
WO/2008/101202A1 |
Compounds of formula (II) R1R2R3N+-(C(R1a)(R2a))-Ar-Z-C(O)-Y-(C(R1)(R2))n-N-(R3)(R4) A-II, in which R1R2R3N+, R1a, R2a, Ar, Z, Y, R1, R2, n, R3, R4 and A- have the meanings given in the specification, are useful as prodrugs for opioids (...
|
|
WO/2008/094909A2 |
This invention is directed to compounds of formula (I): wherein (A), n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug t...
|
|
WO2008036980B1 |
Described herein are prodrugs of the opioid buprenorphine, methods of making them, formulations comprising these prodrugs, and methods of using them. One embodiment described herein relates to the transdermal administration of a buprenor...
|
|
WO/2008/049178A1 |
The present invention describes a new propofol-containing anesthetic pharmaceutical composition for parenteral administration, in the form of an oil-in-water microemulsion in which the oily phase is constituted by propofol in the form of...
|
|
WO/2008/046657A1 |
The present invention relates to compounds or pharmaceutically acceptable salts thereof, to processes for their preparation, to pharmaceutical compositions containing them, and to the use of such compounds in therapeutical use. In partic...
|
|
WO/2008/041075A1 |
The present invention is directed to compounds of formula (I) Wherein R1 to R5, X and Z are further defined in the description. The invention also relates to processes for the preparation of the compounds and to intermediates used in the...
|
|
WO/2008/036858A2 |
The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to r...
|
|
WO/2008/022541A1 |
Disclosed are a series of esters containing 2,6-diisopropylphenyl and tert-amine, the water-soluble derivatives thereof (II) through reaction with acid, and preparation method thereof. The method uses 2,6-diisopropylphenol (I) as a raw m...
|
|
WO/2008/024006A2 |
A pharmaceutical preparation in a gel form, comprising hydrogen peroxide or gentian violet, or iodine as an active agent, and a gelling agent, a solvent and optional auxiliary agents, characterized in that the preparation comprises as a ...
|
|
WO/2008/011670A1 |
The invention provides a method of reducing injury to cells, tissues or organs of a body following trauma by administering a composition to the body following trauma, including: (i) a potassium channel opener or agonist and/or an adenosi...
|
|
WO/2008/011539A2 |
In one embodiment the invention provides novel compounds of Formula (I) as well as prodrugs, salts, hydrates, solvates and N-oxides thereof. The invention also provides pharmaceutical compositions that include such compounds as well as m...
|
|
WO/2008/007554A1 |
An adhesive preparation comprising a support and a medicine-containing layer laminated on the support, wherein the medicine-containing layer comprises at least one compound selected from the group consisting of fentanyl and a pharmaceuti...
|
|
WO/2007/145563A1 |
Compounds of formula I or pharmaceutically acceptable salts thereof: wherein X, A, R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are usef...
|
|
WO/2007/133751A2 |
A stabilized semi-solid delivery vehicle contains a polyorthoester and an excipient, and a pharmaceutical composition contains an active agent, optionally a stabilizing agent, and the delivery vehicle. The pharmaceutical composition may ...
|
|
WO/2007/121976A1 |
The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to spiro[benzopyran] or spiro[benzofuran] derivatives, to processes of preparation of such compounds, to ph...
|
|
WO/2007/111371A1 |
The object is to provide an agent for external application which can be used for amelioration of itching on the hyperesthetic skin. Disclosed is an agent for external application to the skin which can be used for amelioration of itching ...
|
|
WO/2007/111370A1 |
The object is to provide an agent for external application which can be used for ameliorating itching on the skin, particularly itching on the hyperesthetic skin. Disclosed is an agent for external application to the skin, which comprise...
|
|
WO/2007/093617A2 |
The present invention concerns new preservative-free hyperbaric compositions of prilocaine HCI intended for use in intrathecal narcosis, characterized by high stability at ambient temperature (15°C-27°C). The present invention also con...
|
|
WO/2007/079957A1 |
The invention relates to the substituted propiolic acid amides of general formula (I), to methods for producing them, to drugs containing said compounds and to the use thereof for producing drugs.
|
|
WO/2007/066305A1 |
According to the present application there is provided a preparation for use in the prophylaxis or treatment of pain in the human or animal body. The preparation is in the form of one or more sesquiterpene compounds or a composition cont...
|
|
WO/2007/066148A1 |
The present invention relates to compositions for transdermal administration of therapeutic agents for providing a local and sustained therapeutic effect, wherein the extent of systemic administration can be controlled. In particular, th...
|
|
WO/2007/059591A1 |
The present invention provides an oral delivery system for a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof with pharmacological, physiological or biochemical activity. The pr...
|
|
WO/2007/054269A2 |
The invention relates to extracts from the bark of corynanthe species, especially corynanthe pachyceras, and the use thereof for treating and preventing diseases of the urinary tract collecting system, sexual disorders, lipid metabolism ...
|
|
WO/2007/055279A1 |
Disclosed is an iontophoresis preparation for having a physiologically active substance absorbed through the skin or mucosa by using an electrical driving force. The iontophoresis preparation contains a local anesthetic, epinephrine or a...
|
|
WO/2007/052295A2 |
The invention discloses an aqueous anaesthetic Propofol composition that is stable, autoclave sterilized, suitable for parental administration, having reduced incidence of pain upon injection. The composition comprises propofol, 2-hydrox...
|
|
WO/2007/042240A1 |
The invention relates to quaternary α-aminocarboxyamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, X, q and n are as defined in claim 1, for treating diseases and conditions mediated by modulation of voltage-gated sodiu...
|
|
WO/2007/033400A1 |
The invention generally provides a method of treating pain in a patient, the method comprising the step of administering to the patient, an effective dose of Methoxyflurane via an inhaler means. Preferably, the patient is a mammal. The p...
|
|
WO/2007/007057A1 |
Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents, formula (I): R1 represents: (a) -L-A or -...
|
|
WO/2007/006221A1 |
A synergistic time-delaying agent for local anesthetic. The said synergistic time-delaying agent contains dopamine 0.1-100mg, dexamethasone 1-200mg, compound vitamin B 0.5-20mg, metronidazole 10-400mg, berberine 10-1000mg, etamsylate 0.5...
|
|
WO/2006/127639A2 |
The preparation of an injectable solution of ropivacaine by dissolving ropivacaine base in aqueous acidic solution having a molar ratio of acid to ropivacaine base greater than 1:1 eliminates the need for a hydrochloride or hydrochloride...
|
